TARDBP and amyotrophic lateral sclerosis: Following up on their seminal discovery that ATXN2 interacted with TDP-43 and that long-normal ATXN2 repeats were a risk factor of ALS, the Gitler laboratory examined the effects of reducing Atxn2 in vivo.